SI-BONE Résultats passés
Passé contrôle des critères 0/6
SI-BONE a connu une croissance annuelle moyenne de ses bénéfices de 18.8%, tandis que le secteur Medical Equipment a vu ses bénéfices augmenter de en hausse à 13.6% par an. Les revenus ont augmenté de en hausse à un taux moyen de 19.9% par an.
Informations clés
18.77%
Taux de croissance des bénéfices
24.53%
Taux de croissance du BPA
| Medical Equipment Croissance de l'industrie | 8.90% |
| Taux de croissance des recettes | 19.87% |
| Rendement des fonds propres | -9.33% |
| Marge nette | -8.10% |
| Dernière mise à jour des bénéfices | 31 Mar 2026 |
Mises à jour récentes des performances passées
Recent updates
Mise à jour du récit • May 22
SIBN: 2026 Guidance And Trauma Partnership Will Drive Further Upside
Analysts have trimmed their price target on SI-BONE from $22.00 to $18.00 as updated assumptions now reflect slightly lower revenue growth, a modestly reduced profit margin outlook, and a lower future P/E multiple, partly offset by a small adjustment to the discount rate. What's in the News SI-BONE issued earnings guidance for 2026, with worldwide revenue expected in a range of $228.5 million to $232.5 million, implying year-over-year growth of about 14% to 16% (Key Developments).Article d’analyse • May 14
Analysts Have Been Trimming Their SI-BONE, Inc. (NASDAQ:SIBN) Price Target After Its Latest Report
SI-BONE, Inc. ( NASDAQ:SIBN ) just released its latest first-quarter results and things are looking bullish. Results...Mise à jour du récit • Apr 12
SIBN: 2026 Guidance And Trauma Partnership Will Support Further Upside
Analysts have kept SI-BONE's price target steady at $22.00, citing only modest tweaks to inputs such as the discount rate, revenue growth, profit margin, and forward P/E assumptions, rather than any major change in their overall view. What's in the News Smith+Nephew signed a distribution agreement with SI-BONE focused on the iFuse TORQ portfolio for percutaneous pelvic fracture fixation procedures and sacroiliac joint fusion, expanding access to these products through Smith+Nephew's trauma portfolio and SI-BONE's existing sales channel (Key Developments).Mise à jour du récit • Mar 29
SIBN: 2026 Outlook And Pelvic Fixation Partnership Will Support Upside
Analysts now hold their price target for SI-BONE steady at $22.00. This reflects only small tweaks to assumptions around discount rate, revenue growth, profit margin, and future P/E that do not materially shift their overall valuation view.Mise à jour du récit • Mar 11
SIBN: 2026 Revenue Outlook And Pelvic Fixation Deal Will Support Upside
Analysts have held their SI-BONE price target steady at $22.00, with only modest tweaks to assumptions on discount rate, revenue growth, profit margin, and future P/E, reflecting fine tuning rather than a shift in their overall view. What's in the News Smith+Nephew signed a distribution agreement with SI-BONE focused on the iFuse TORQ portfolio for percutaneous pelvic fracture fixation procedures and sacroiliac (SI) joint fusion, broadening access to these products through Smith+Nephew's trauma channel alongside SI-BONE's existing salesforce (Key Developments).Mise à jour du récit • Feb 25
SIBN: 2026 Revenue Outlook And New Distribution Deal Will Support Upside
Analysts have trimmed their price target for SI-BONE from $23.00 to $22.00, reflecting updated assumptions that include slightly lower revenue growth expectations, a modestly higher profit margin outlook, and a revised forward P/E multiple. What's in the News SI-BONE issued earnings guidance for 2026, projecting worldwide revenue in a range of $228.5 million to $232.5 million, with implied year over year growth guidance of about 14% to 16% (company guidance).Mise à jour du récit • Jan 19
SIBN: Higher 2025 Revenue Guidance Will Support Future Upside Potential
Analysts have maintained their fair value estimate for SI-BONE at $23.00. They made small adjustments to assumptions such as discount rate, revenue growth, profit margin, and future P/E, which together support this reaffirmed target.Mise à jour du récit • Jan 04
SIBN: Raised 2025 Revenue Guidance Will Drive Stronger Profitability And Share Price Upside
Analysts have modestly lowered their price target on SI-BONE to 23.00 dollars per share, reflecting a slightly higher discount rate and a marginally lower expected future price to earnings multiple, even as they factor in stronger long term revenue growth prospects. What's in the News SI-BONE raised its 2025 revenue guidance to a range of 198 million to 200 million dollars, up from 195 million to 198 million dollars previously.Mise à jour du récit • Dec 19
SIBN: Raised Revenue Guidance Will Support Stronger Profitability And Share Price Upside
Analysts have raised their price target on SI-BONE from 20 dollars to 23 dollars, citing slightly stronger expectations for revenue growth, profitability, and long term valuation multiples. What's in the News Company raised 2025 revenue guidance to a range of 198 million dollars to 200 million dollars, up from a prior range of 195 million dollars to 198 million dollars, signaling increased confidence in demand trends (company guidance filing) The updated outlook implies faster top line growth than previously anticipated and supports analysts' upward revisions to price targets and long term valuation assumptions (company guidance filing) The narrowing of the revenue guidance range suggests greater visibility into procedure volumes and commercial execution for the remainder of the year (company guidance filing) Valuation Changes The fair value estimate has risen slightly from 20 dollars to 23 dollars per share, reflecting modestly stronger growth and profitability assumptions.Article d’analyse • Nov 13
Earnings Update: SI-BONE, Inc. (NASDAQ:SIBN) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts
SI-BONE, Inc. ( NASDAQ:SIBN ) just released its third-quarter report and things are looking bullish. Revenues and...Article d’analyse • Nov 12
Getting In Cheap On SI-BONE, Inc. (NASDAQ:SIBN) Might Be Difficult
SI-BONE, Inc.'s ( NASDAQ:SIBN ) price-to-sales (or "P/S") ratio of 4.1x may not look like an appealing investment...Article d’analyse • Jun 26
Is SI-BONE (NASDAQ:SIBN) Using Debt In A Risky Way?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Article d’analyse • May 09
Earnings Update: SI-BONE, Inc. (NASDAQ:SIBN) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts
SI-BONE, Inc. ( NASDAQ:SIBN ) investors will be delighted, with the company turning in some strong numbers with its...Article d’analyse • May 08
Revenues Tell The Story For SI-BONE, Inc. (NASDAQ:SIBN) As Its Stock Soars 30%
SI-BONE, Inc. ( NASDAQ:SIBN ) shareholders would be excited to see that the share price has had a great month, posting...Article d’analyse • Mar 27
SI-BONE (NASDAQ:SIBN) Has Debt But No Earnings; Should You Worry?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Nouveau récit • Mar 26
TORQ And TNT Will Expand Market Reach In 2025
Strong product launches and a robust innovation pipeline suggest promising future revenue growth and strengthened market positioning.Article d’analyse • Jan 19
SI-BONE, Inc. (NASDAQ:SIBN) Looks Just Right With A 26% Price Jump
SI-BONE, Inc. ( NASDAQ:SIBN ) shareholders have had their patience rewarded with a 26% share price jump in the last...Article d’analyse • Nov 04
Market Cool On SI-BONE, Inc.'s (NASDAQ:SIBN) Revenues
There wouldn't be many who think SI-BONE, Inc.'s ( NASDAQ:SIBN ) price-to-sales (or "P/S") ratio of 3.7x is worth a...Article d’analyse • Sep 25
Is SI-BONE (NASDAQ:SIBN) Using Too Much Debt?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Article d’analyse • Apr 01
SI-BONE, Inc.'s (NASDAQ:SIBN) P/S Is On The Mark
SI-BONE, Inc.'s ( NASDAQ:SIBN ) price-to-sales (or "P/S") ratio of 4.8x might make it look like a sell right now...Article d’analyse • Feb 29
Analyst Estimates: Here's What Brokers Think Of SI-BONE, Inc. (NASDAQ:SIBN) After Its Full-Year Report
It's been a sad week for SI-BONE, Inc. ( NASDAQ:SIBN ), who've watched their investment drop 14% to US$17.35 in the...Article d’analyse • Feb 28
Is SI-BONE (NASDAQ:SIBN) Using Debt In A Risky Way?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Article d’analyse • Nov 12
Is SI-BONE (NASDAQ:SIBN) Using Too Much Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Article d’analyse • Aug 09
Is SI-BONE (NASDAQ:SIBN) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Article d’analyse • Apr 20
Is SI-BONE (NASDAQ:SIBN) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Article d’analyse • Jan 01
Is SI-BONE (NASDAQ:SIBN) Using Debt In A Risky Way?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Ventilation des recettes et des dépenses
Ventilation des recettes et des dépenses
Comment SI-BONE gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 31 Mar 26 | 206 | -17 | 167 | 17 |
| 31 Dec 25 | 201 | -19 | 165 | 17 |
| 30 Sep 25 | 194 | -22 | 163 | 17 |
| 30 Jun 25 | 185 | -24 | 158 | 17 |
| 31 Mar 25 | 177 | -27 | 154 | 17 |
| 31 Dec 24 | 167 | -31 | 151 | 17 |
| 30 Sep 24 | 157 | -37 | 147 | 17 |
| 30 Jun 24 | 151 | -41 | 146 | 17 |
| 31 Mar 24 | 144 | -43 | 144 | 16 |
| 31 Dec 23 | 139 | -43 | 141 | 15 |
| 30 Sep 23 | 132 | -44 | 139 | 14 |
| 30 Jun 23 | 124 | -48 | 137 | 14 |
| 31 Mar 23 | 117 | -55 | 139 | 13 |
| 31 Dec 22 | 106 | -61 | 137 | 14 |
| 30 Sep 22 | 100 | -65 | 135 | 13 |
| 30 Jun 22 | 96 | -66 | 132 | 13 |
| 31 Mar 22 | 92 | -62 | 125 | 13 |
| 31 Dec 21 | 90 | -57 | 119 | 12 |
| 30 Sep 21 | 87 | -51 | 112 | 12 |
| 30 Jun 21 | 85 | -45 | 105 | 11 |
| 31 Mar 21 | 77 | -43 | 96 | 10 |
| 31 Dec 20 | 73 | -44 | 94 | 9 |
| 30 Sep 20 | 71 | -44 | 92 | 9 |
| 30 Jun 20 | 67 | -46 | 90 | 8 |
| 31 Mar 20 | 69 | -42 | 90 | 8 |
| 31 Dec 19 | 67 | -38 | 86 | 7 |
| 30 Sep 19 | 63 | -35 | 79 | 7 |
| 30 Jun 19 | 60 | -28 | 72 | 7 |
| 31 Mar 19 | 58 | -23 | 64 | 6 |
| 31 Dec 18 | 55 | -17 | 57 | 5 |
| 30 Sep 18 | 54 | -17 | 54 | 4 |
| 30 Jun 18 | 52 | -18 | 55 | 4 |
| 31 Mar 18 | 49 | -21 | 55 | 4 |
| 31 Dec 17 | 48 | -23 | 56 | 5 |
| 31 Mar 17 | 44 | -21 | 49 | 6 |
| 31 Dec 16 | 42 | -21 | 49 | 5 |
| 31 Mar 16 | 40 | -27 | 54 | 8 |
| 31 Dec 15 | 41 | -28 | 54 | 9 |
| 30 Sep 15 | 42 | -32 | 56 | 8 |
Des revenus de qualité: SIBN n'est actuellement pas rentable.
Augmentation de la marge bénéficiaire: SIBN n'est actuellement pas rentable.
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: SIBN n'est pas rentable, mais a réduit ses pertes au cours des 5 dernières années à un taux de 18.8% par an.
Accélération de la croissance: Impossible de comparer la croissance des bénéfices de SIBN au cours de l'année écoulée à sa moyenne sur 5 ans car elle n'est actuellement pas rentable
Bénéfices par rapport au secteur d'activité: SIBN n'est pas rentable, ce qui rend difficile la comparaison de sa croissance des bénéfices de l'année écoulée avec celle du secteur Medical Equipment ( 14.8% ).
Rendement des fonds propres
ROE élevé: SIBN a un retour sur capitaux propres négatif ( -9.33% ), car il n'est actuellement pas rentable.
Rendement des actifs
Rendement des capitaux employés
Découvrir des entreprises performantes dans le passé
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/05/26 11:44 |
| Cours de l'action en fin de journée | 2026/05/22 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
SI-BONE, Inc. est couverte par 16 analystes. 8 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Travis Steed | BofA Global Research |
| Caitlin Cronin | Canaccord Genuity |
| Ross Osborn | Cantor Fitzgerald & Co. |